Energy Transfer from Systole to Diastole: A Novel Device-Based Approach for the Treatment of Heart Failure with Preserve Ejection Fraction

Introduction

CorAssist is developing innovative medical device for Heart Failure with preserve ejection fraction (HFpEF). HFpEF is a clinical syndrome that impairs the ability of the left ventricle (LV) to fill with blood, due to impaired LV relaxation and/or stiffened myocardium. It is accompanied by the symptoms and signs of pulmonary and/or peripheral congestion.

Heart failure afflicts 5.7 million people in the US. HFpEF accounts for ~50% of all heart failure cases. At present, there are no proven pharmaceutical or device based therapeutic solutions for HFpEF patients.

CorAssist has developed "spring like" devices which harness the elastic energy produced by the LV during systole (contraction) and release the energy to the LV during diastole (relaxation) to augment LV diastolic dynamics. The devices do not require any power source.

Addressable Market

CorAssist targets patients with relatively severe HFpEF (class III & IV). An estimated 1.5 million patients in US and Europe would be suitable for implantation of CorAssist`s CORolla^® product, indicating a total available annual market of over $1.7 billion.

Product and Clinical Status

The primary product CORolla^® (Intra-Left-Ventricular device), is an implantable elastic spring-like device designed in the shape of 3 arms. The device is implanted through Trans-Apical Approach (TAA) by cardiac surgeons.

First In Men stand-alone implantation done on July,2017 at Rambam Healthcare Campus.

Milestones

Complete 3 subjects implanted by Q2 2018

Complete 10 subjects by Q4 2019